Abstract
Objectives To: 1) evaluate the effectiveness of COVID-19 vaccines among South Asians living in Ontario, Canada compared to non-South Asians, and 2) compare the odds of symptomatic COVID-19 infection and related hospitalizations and deaths among non-vaccinated South Asians and non-South Asians.
Design Test negative design study
Setting Ontario, Canada between Dec 14, 2020 and Nov 15, 2021
Participants All eligible individuals >18 years with symptoms of COVID-19 and subdivided by South Asian ethnicity versus other, and those who were vaccinated versus non-vaccinated.
Main Outcome measures The primary outcome was vaccine effectiveness as defined by COVID-19 infections, hospitalizations, and deaths, and secondary outcome was the odds of COVID-19 infections, hospitalizations, and death comparing non-vaccinated South Asians to non-vaccinated non-South Asians.
Results 883,155 individuals were included. Among South Asians, two doses of COVID-19 vaccine prevented 93.8% (95% CI 93.2, 94.4) of COVID-19 infections and 97.5% (95% CI 95.2, 98.6) of hospitalizations and deaths. Among non-South Asians, vaccines prevented 86.6% (CI 86.3, 86.9) of COVID-19 infections and 93.1% (CI 92.2, 93.8) of hospitalizations and deaths. Non-vaccinated South Asians had higher odds of symptomatic SARS-CoV-2 infection compared to non-vaccinated non-South Asians (OR 2.35, 95% CI 2.3, 2.4), regardless of their immigration status.
Conclusions COVID-19 vaccines are effective in preventing infections, hospitalizations and deaths among South Asians living in Canada. The observation that non-vaccinated South Asians have higher odds of symptomatic COVID-19 infection warrants further investigation.
What is already known?Some ethnic communities, such as South Asians, were disproportionately impacted during the COVID-19 pandemic. However, there are limited data on COVID-19 vaccine efficacy among this high-risk ethnic group.
What this study adds?
- In this large population-based study including close to 900,000 individuals in Canada, we show COVID-19 vaccines are effective in preventing symptomatic SARS CoV-2 infections, hospitalizations and deaths among both South Asians and non-South Asians.
- We also demonstrate that, among non-vaccinated individuals, South Asians have higher odds of COVID-19 infection, and an increased risk of COVID-19 hospitalizations and deaths compared to non-South Asians.
Competing Interest Statement
Dr. Anand holds a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease, and the Michael G DeGroote Heart and Stroke Foundation of Canada Chair in Population Health Research. Dr. Loeb sits on Vaccine advisory boards for Seqirus, Pfizer, Sanofi, Medicago, GSK, Merck, Noravax; DSMB for CanSino Biologics. Dr Shah is funded by the University of Toronto as the Novo Nordisk Research Chair in Equitable Care of Diabetes and Related Conditions. Other authors declare that they have no competing interests.
Funding Statement
This study received funding from the COVID-19 Immune Task Force through the Public Health Agency of Canada. This study was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). This work was also supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontario's ongoing response to COVID-19 and its related impacts.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ICES-based studies are not required to be reviewed by a research ethics committee or institutional board. This is stated in the Canadian Personal Health Information Protection Act.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing interest: Dr. Anand holds a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease, and the Michael G DeGroote Heart and Stroke Foundation of Canada Chair in Population Health Research.
Dr. Loeb sits on Vaccine advisory boards for Seqirus, Pfizer, Sanofi, Medicago, GSK, Merck, Noravax; DSMB for CanSino Biologics.
Dr Shah is funded by the University of Toronto as the Novo Nordisk Research Chair in Equitable Care of Diabetes and Related Conditions.
Other authors declare that they have no competing interests.
Data Availability
All data is available in the ICES databases.
